Loading...
Annual brain MRI is commonly used in patients with multiple sclerosis (MS) receiving disease-modifying therapy to monitor disease activity and treatment-related complications. However, ocrelizumab strongly suppresses inflammatory activity, raising questions about the value of yearly imaging in clinically stable patients.
This observational registry analysis included 342 patients with MS and 1639 follow-up scans in which investigators evaluated the frequency of radiologic disease activity during ocrelizumab treatment and estimated the number needed to scan (NNS) to detect one MRI showing new activity.
Radiologic disease activity was detected on ≈2% of scans and ≈7% of patients.
Three patients switched disease-modifying therapy…